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A B S T R A C T
Cardiac arrest constitutes an extremely life-threatening condition that inevitably and 
promptly results in death if left untreated. Cardiac arrest outcomes still remain very 
poor, especially when the presenting cardiac rhythm is nonshockable. Important, re-
cent, clinical research has focused on the quality of cardiopulmonary resuscitation 
(CPR), the mechanical augmentation of the circulation during CPR, CPR drugs, and 
therapeutic hypothermia. Chest compression depth of at least 51 mm increases the 
probability of neurologically favorable survival. Despite initially promising results, a 
large effectiveness study failed to confirm the efficacy of the mechanical augmentation 
of the circulation. Epinephrine has finally been shown to slightly improve functional 
outcome after out-of-hospital cardiac arrest, especially when given early. In a recent, 
in-hospital study of 268 patients, the addition of vasopressin and methylprednisolone 
during CPR and the administration of hydrocortisone in postresuscitation shock im-
proved functional outcome after vasopressor-requiring cardiac arrest; however, corti-
costeroid efficacy still needs to be separately confirmed in a large, international trial. 
Lastly, preliminary human data may support the conduct of high quality trials evaluat-
ing the efficacy of beta adrenergic antagonists in shockable cardiac arrest, and nitrates 
may warrant evaluation in the clinical setting. The purpose of this paper is to review 
these potentially important advances in the management of cardiac arrest.
I N T R O D U C T I O N
New out-of-hospital and in-hospital cardiac arrest statistics sourced from the Re-
suscitation Outcomes Consortium Cardiac Registry and Get With The Guidelines®-
Resuscitation data show that the incidence of cardiac arrest with any initial rhythm 
is not decreasing,1 despite recent advances in preventive medicine and interventional 
therapeutic strategies. As for in-hospital cardiac arrest, a study published in 2011, 
concluded that its incidence may actually be increasing.2 This is important for under-
standing the burden of in-hospital cardiac arrest and developing strategies to improve 
care for hospitalized patients.
A large registry study in the United States showed no significant change in survival 
to discharge among elderly, hospitalized patients treated with cardiopulmonary resus-
citation (CPR) for cardiac arrest from 1992 to 2005.3 However, a more recent registry 
study indicates that both survival to hospital discharge and neurological outcome im-
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proved substantially within 2000-2009.4 Still, rates of survival 
to hospital discharge with favorable neurological outcome 
remain low, i.e. approximately 16% in 2009; pooled data from 
vasopressor-requiring and non-vasopressor-requiring cardiac 
arrest.4 Thus, further research aimed at improving survival and 
neurological recovery of cardiac arrest patients is considered 
as imperative.
Cardiac arrest etiology encompasses a variety of cardiac 
and noncardiac underlying pathologies. Also, cardiac arrest 
can occur under different circumstances (e.g. in the presence 
or absence of witnesses), and settings (e.g. out-of-hospital or 
in-hospital). This heterogeneity suggests that a single approach 
to resuscitation may be unrealistic; however, a core bundle of 
actions results in a universal strategy for achieving successful 
resuscitation. These actions are termed as the links in the 
“Chain of Survival”.
The purpose of the current article is to review recent, 
clinical evidence-based advances in treating patients with 
cardiac arrest from practices of basic life support (BLS) and 
advanced life support (ALS) to the post-resuscitation phase 
in the intensive care unit.
K E y  C h A N G E S  A N D  C O N T I N U E D 
P O I N T S  O f  E m P h A S I S  f R O m  T h E  2 0 0 5 
B L S  G U I D E L I N E S 
Prompt recognition of cardiac arrest and action by the 
rescuer continue to be priorities for the 2010 American Heart 
Association (AHA) Guidelines for CPR and emergency cardio-
vascular care.5 Rescuers should start CPR immediately if the 
adult victim is unresponsive and not breathing or only gasping. 
The “look, listen, and feel” for breathing is no longer recom-
mended. Authors emphasize on uninterrupted (interruptions 
of less than 10 seconds) and efficient chest compressions. 
Compressions take priority over airway and breathing, due 
to the fact that the majority of cardiac arrests in adults result 
from a primary cardiac cause and thus the major problem is 
that oxygen delivery to the heart and brain is limited by blood 
flow rather than by arterial oxygen content.6, 7 CPR sequence 
has now changed to Circulation-Airway-Breathing. Guideline 
experts advise on pushing hard (at least 50 mm) and fast (rate: 
100/min), while still allowing full recoil of the chest during 
decompression. Moreover, experts advise against “excessive 
ventilation”. The compression to ventilaton ratio is 30:2, 
and when an artificial airway is established, 1-second-lasting 
breaths (rate: 8-10/min), and asynchronous with compressions 
are considered as adequate. While positive-pressure ventila-
tion has been a mainstay of CPR, it has recently come under 
scrutiny because of the potential for the increased intrathoracic 
pressure’s impeding of the venous return to the heart. 
C I R C U L A T O R y  S U P P O R T  -  C h E S T 
C O m P R E S S I O N S  -  f I R S T  P R I O R I T y
The “Hands-Only CPR” campaign is now being led by 
AHA across the United States. There are multiple reasons 
“chest compression only CPR” (COCPR) might have ad-
vantages over conventional CPR. These include the rapid 
deterioration of forward blood flow that occurs during an even 
brief interruption of chest compressions,8,9 the long ramp-up 
time to return to adequate blood flow after resuming chest 
compressions,8,9 the reduction in cardiac venous return during 
positive pressure ventilation,10 the complexity of conventional 
CPR,11,12 the significant time required to administer the arti-
ficial breaths,12-14 and the critical importance of cerebral and 
coronary circulation during cardiac arrest.8,9,15,16
An increase in the rate of bystanders’ willingness to per-
form COCPR has been observed. A recent study has evalu-
ated the rate of bystander CPR, as well as survival to hospital 
discharge, when COCPR has been performed.17 This prospec-
tive, observational, cohort analysis included 4415 patients who 
experienced out of hospital cardiac arrest of presumed cardiac 
etiology. There was a significant difference in good neurologi-
cal recovery (cerebral performance category score of 1 or 2) 
between the COCPR group (62/814; 7.6%; 95% confidence 
interval -CI, 5.8%-9.4%) and the conventional CPR group 
(34/651; 5.2%; 95% CI, 3.5%-6.9%) (P<0.001).17 Furthermore, 
the largest of the COCPR vs conventional CPR studies,18 also 
found a statistically significant increase in neurologically intact 
survival with COCPR (18.9% vs. 13.5%, P = 0.03). COCPR 
should not be preferred in victims of asphyxial cardiac arrest 
(e.g. in the setting of drowning), as in such cases, the prompt 
reversal of the hypoxemia through ventilation is critical for 
the restoration of spontaneous circulation (ROSC) and the 
achievement of a favorable functional outcome.19,20 
A coronary perfusion pressure (CPP) of at least 15 mmHg 
is required to achieve ROSC.5 Several authors suggest that 
chest compressions of 38–51 mm are not deep enough for 
ROSC.21–24 Finally, several reports demonstrate that chest 
compressions deeper than 51 mm are associated with improved 
short term outcomes.25–28 This chest compression depth is also 
recommended by the current Guidelines.29,30
In a recent analysis,31 the authors evaluated whether the 
depth of chest compressions provided by prehospital rescu-
ers is independently associated with survival and favorable 
functional outcome. This study included 593 adults with 
out-of-hospital arrest (OHCA) of presumed cardiac etiology. 
Chest compression quality was measured during resuscitation, 
including minute-by-minute rate and depth data. Interruptions 
in compressions were assessed using the chest compression 
fraction, i.e. the percentage of time compressions were per-
formed throughout the entire resuscitation procedure. Chest 
compression rate was similar for survivors 113.5 (95% CI 
108.5–118.6) and non-survivors 112.7 (95% CI 110.9–114.4). 
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Chest compression depth was significantly greater in survivors 
(53.6 mm; 95% CI 50.5–56.7) than in non-survivors (48.8 mm; 
95% CI 47.6–50.0). Notably, the median percentage of chest 
compressions of at least 51 mm was 64.0% (95% CI 47.0–81.0) 
for survivors and 45.0% (95% CI 39.6–50.4) for non-survivors. 
The odds of survival increased by 29% for every 5 mm 
increase in mean chest compression depth (adjusted odds 
ratio - OR = 1.29; 95% CI 1.00–1.65). Likewise, a favorable 
functional outcome had 30% better odds for each 5 mm in-
crease in chest compression depth (adjusted OR = 1.30; 95% 
CI 1.00–1.70). Furthermore, the odds of survival to hospital 
discharge and favorable functional outcome increased by 21% 
for each 10% increment of chest compressions of at least 51 
mm. In addition, survivors were more likely to have been 
treated with mean chest compression depth of at least 51 mm 
as compared with non-survivors (64% vs. 45%). However, 
while deeper chest compressions were positively associated 
with improved outcomes, the optimal chest compression depth 
remains unknown.
D E f I B R I L L A T I O N
Defibrillation is the application of a preset electrical 
current across the myocardium to cause synchronous depo-
larization of the cardiac muscle. In ventricular fibrillation 
(VF) / ventricular tachycardia (VT) cardiac arrest, the goal of 
defibrillation is to restore an organized cardiac rhythm (ideally 
normal sinus rhythm) that will result in ROSC. Defibrillators 
work as capacitors discharging their stored energy through a 
circuit that includes the patient’s heart. Optimal, monophasic 
and biphasic defibrillator current (I) ranges within 30-40 A 
and 15-20 A, respectively.32 Current duration (t) ranges within 
10-20 ms, and the adult patient transthoracic impedance (R) 
usually ranges within 70-80 Ω. 32 The energy delivered to the 
patient is proportional to the stored charge (Q) and the ca-
pacitor voltage (V): 
Energy = ½ · Q ·V = ½ ·(I t) ·(I ·R) = ½ ·I2 ·R ·t.
For monophasic defibrillators, the recommended energy 
level is 360 J. For biphasic defibrillators, the initial energy 
level should be at least 150 J.32 The sum of the defibrillator’s 
electrode areas should be at least 150 cm2,33 and a force of 8 
kg should be applied on them, in order to minimize R and thus 
maximize current flow through the heart.32
The use of automated external defibrillators (AEDs) has 
revolutionized the capability of timely delivery of defibrillation 
to VF/VT victims. The availability of AEDs is currently recom-
mended for both public, out-of-hospital and non-monitored, 
in-hospital settings.32 The safety and effectiveness of AEDs 
with respect to prompt defibrillation and survival is supported 
by a considerable amount of previously published data.34 
Nevertheless, in a recent retrospective analysis of OHCA the 
use of AEDs by bystanders was quite infrequent, i.e. an AED 
was retrieved and used successfully before ambulance arrival 
in less than 2% of 1035 OHCA cases.35 
Whenever the first shock is preceded by CPR, the delay 
between chest compression interruption and shock delivery 
(pre-shock pause) should be kept to less than 5 s, and chest 
compressions should be resumed immediately after the shock.32 
There is currently insufficient data to support or refute a 
pre-specified period of 2-3 min of pre-shock CPR in the out-
of-hospital setting.32 However, regarding in-hospital VF/VT, 
defibrillation should be administered as soon as possible. De-
fibrillation in the (early) electrical phase (i.e. within 1-3 min of 
VF/VT onset) has a high probability of success that may exceed 
90%, especially when a biphasic waveform is used.32 Patients 
experiencing VF/VT in the cardiac catheterization laboratory 
or following cardiac surgery may be treated with three quick 
successive (stacked) shocks.32 In all other cases of in-hospital 
or out-of-hospital VF/VT, shocks should be interspersed with 
2-min periods of chest compressions and vasopressors and 
antiarrhythmics should be given after the third shock.32 
The optimal energy for defibrillation is that which achieves 
VF/VT termination and ROSC whilst causing the minimum 
of myocardial damage.32,36 Biphasic vs monophasic waveforms 
are more effective at terminating ventricular arrhythmias at 
lower energy levels, and have greater first shock efficacy.32,37-39 
However, the potential superiority of biphasic waveforms with 
respect to neurologically favourable survival still remains to 
be demonstrated.32
Multiple clinical studies suggest that it is possible to pre-
dict the success of defibrillation from VF waveform analysis 
with varying reliability.40 However, a recent, multicenter study 
comparing a VF waveform analysis algorithm for identification 
of VF unlikely to respond to immediate defibrillation with a 
standard shock-first protocol failed to show any waveform 
analysis-associated improvement in survival to hospital dis-
charge.41 Consequently, the value of VF waveform analysis 
remains uncertain.40 
m E C h A N I C A L  A U G m E N T A T I O N  O f 
C I R C U L A T I O N
Over the past 25 years, a variety of alternatives to con-
ventional, manual CPR have been developed in an effort to 
enhance perfusion during attempted resuscitation from cardiac 
arrest and to improve survival. In the 2010 AHA guidelines,42 
the authors warn that usage of such devices may delay or inter-
rupt CPR. They claim that these devices typically require more 
personnel, training, and equipment, or they apply to a specific 
setting. In recent bibliography, there is a lot of debate about 
active compression-decompression (ACD-CPR) CPR, applied 
in conjunction with the impendence threshold device (ITD).
ACD-CPR is performed with a device that includes a suc-
tion cup to actively lift the anterior chest during decompression 
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(Fig. 1). The application of external negative suction during the 
decompression phase of CPR creates negative intrathoracic 
pressure, thus potentially enhancing venous return to the heart.
The ITD is a pressure-sensitive valve that is attached to an 
endotracheal tube, supraglottic airway, or face mask (Fig. 2). 
The ITD limits air entry into the lungs during the decompres-
sion phase of CPR, creating negative intrathoracic pressure 
and improving venous return to the heart and cardiac output 
during CPR. 43-46 It does so without impeding positive pressure 
ventilation or passive exhalation. Studies of the mechanisms 
involved in animals and humans provide the physiological 
underpinnings for “the other side of breathing”: to increase 
circulation to the heart and brain. Α review article 47 on the 
effects of the respiratory pump to improve vital organ perfu-
sion by ITD, described studies that focused on the fundamental 
relationship between the generation of negative intrathoracic 
pressure during inspiration through a low-level of resistance 
created by an ITD and the physiologic effects of a respiratory 
pump. A decrease in intrathoracic pressure during inspiration 
through a fixed resistance resulting in an intrathoracic pressure 
of -7 cmH2O has multiple physiological benefits, including en-
hanced venous return, cardiac stroke volume and aortic blood 
pressure, lower intracranial pressure; resetting of the cardiac 
baroreflex, elevated cerebral blood flow oscillations, and an 
increased tissue blood flow/pressure gradient.
Already in the early 2000s, some studies reported that 
the combination of ACD-CPR and ITD, when performed 
correctly, results in an increase of more than 50% in coro-
nary perfusion pressure, and an improved 24-hour survival 
fIGURE 2. The impedance threshold device (A) and its working 
principle (B; reproduced with permission from Lurie KG et al 
Respir Care 2003;48(1):52–57). 
fIGURE 1. The active compression-decompression device.
and neurological function in cardiac arrest patients.48,49 The 
results of a presumed cardiac-cause OHCA, multicenter, 
randomized, unblinded trial, demonstrated a relative increase 
of 53% in survival to hospital discharge with favorable neu-
rological outcome, when a combination of ACD-CPR and 
ITD was applied compared with standard CPR.50 One year 
after OHCA, survival was still higher (by more than 50%) in 
the intervention group and there were similar proportions of 
restoration of neurologic function in both groups. There was 
no significant difference in the overall major adverse event 
rates between groups. However, pulmonary edema was more 
common in the intervention group. The aforementioned study 
further demonstrated that it is practicable to teach and imple-
ment ACD-CPR and ITD skills in urban, suburban, and rural 
Emergency Service environments.
Opposed to this study is a large effectiveness trial, which 
did not confirm a survival advantage with the use of an ITD 
during standard CPR in patients with nontraumatic OHCA.51 
The authors suggested that the neutral results could have been 
due to the fact that the ITD may not generate or its use by the 
Emergency Service systems couldn’t recreate the proposed 
physiological benefits. Another possible explanation was that 
the ITD did generate the physiological effects seen in experi-
mental studies but couldn’t change clinical outcomes. 
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E P I N E P h R I N E 
The primary goal of pharmacologic therapy during cardiac 
arrest is to facilitate restoration and maintenance of a perfus-
ing, spontaneous rhythm. Toward this goal, ALS drug therapy 
during CPR is often associated with increased rates of ROSC 
and survival to hospital admission but not increased rates of 
long-term survival with good neurological outcome.
One study randomized patients to intravenous or no 
intravenous medications during OHCA.52 The study dem-
onstrated higher rates of ROSC in the intravenous vs the no 
intravenous group (40% vs 25%; OR 1.99; 95% CI 1.48 to 
2.67), but there was no significant difference in the survival 
to hospital discharge (10.5% vs. 9.2%; OR 1.16; 95% CI 0.74 
to 1.82), or the survival to hospital discharge with favorable 
neurological outcome (9.8% vs. 8.1%; OR 1.24; 95% CI 0.77 
to 1.98). Among patients randomized to intravenous access, 
79% received epinephrine, 46% atropine and 17% amiodar-
one, and it was not possible to determine the efficacy of these 
drugs (either individually or in combination) with respect to the 
reported outcomes. Furthermore, as the intervention could not 
be blinded, the potential for paramedics to respond differently, 
particularly when knowing that patients randomized to the no 
intravenous access group would have drug therapy withheld, 
may have introduced a bias. While the investigators identified 
no difference in a number of CPR quality measures across both 
study arms in the 75% of events assessed, the potential bias 
inherent with non-blinding could not be ruled out.
Accordingly, the first randomized, double-blind, placebo-
controlled trial of epinephrine in OHCA reported that 
epinephrine increases ROSC but not survival to hospital dis-
charge.53 A recent review of epinephrine in OHCA54 included 
another four prospective cohort studies,55-58 one retrospective 
cohort study,59 one survival analysis,60 and one case control 
study.61 The authors of the review reported on the paucity 
of supporting evidence for the use of epinephrine in OHCA. 
Several experts have recently suggested that new, large, ran-
domized, controlled trials may be needed to reliably establish 
the effect of epinephrine on the survival to hospital discharge 
and neurological outcome.
A recent, retrospective analysis of prospectively collected, 
population-based data (n=49165 adults with witnessed OHCA 
of cardiac origin) showed that epinephrine administration 
within 10 min of collapse was associated with improved sur-
vival to hospital discharge (OR 1.73; 95% CI 1.46 to 2.04) and 
good neurological outcome (OR 1.39, 95% CI 1.08 to 1.78).62 
Epinephrine effectiveness has been now reconfirmed by a large 
propensity analysis showing a slightly improved, neurologically 
favorable survival with epinephrine use vs. no use (0.7% vs. 
0.4%; OR 1.57 95% CI 1.04 to 2.37) in 9058 pairs of patients 
with nonshockable OHCA.63 Another recent review of 20909 
in-hospital cardiac arrest events showed that increasing the 
epinephrine dosing interval from the guideline-recommended 
of 3-5 min to 6-10 min was associated with improved survival 
to hospital discharge (adjusted ORs 1.30-2.17; 95% CIs 1.02-
1.62 to 1.65-2.92).64 Consequently, future trials should also 
determine the optimal timing of epinephrine administration 
(initial and dosing interval) as well. 
V A S O P R E S S I N  A N D  S T E R O I D S
In a previous, single-center, randomized, controlled 
study,65 combined vasopressin-epinephrine during CPR and 
corticosteroid supplementation during and after CPR vs. 
epinephrine alone during CPR and no steroids resulted in 
improved overall survival to hospital discharge. Patients in 
the vasopressin-steroids epinephrine (VSE) group had more 
frequent ROSC, and attenuated postresuscitation systemic 
inflammatory response65, 66 and organ dysfunction.65 This pre-
liminary study could not reliably assess VSE efficacy with re-
spect to neurologically favorable survival to hospital discharge. 
The current authors addressed this question with a 3-center 
study of vasopressor-requiring, in-hospital cardiac arrest;67 the 
study protocol was identical to that of the preliminary study.65 
This randomized, controlled trial included 268 consecutive 
patients with cardiac arrest requiring epinephrine according 
to resuscitation guidelines (from 364 patients assessed for 
eligibility). Patients received either vasopressin (20 IU/CPR 
cycle) plus epinephrine (1 mg/CPR cycle; cycle duration ap-
proximately 3 min) (VSE group, n = 130) or saline placebo plus 
epinephrine (1 mg/CPR cycle; cycle duration approximately 3 
min) (control group, n = 138) for the first 5 CPR cycles after 
randomization, followed by additional epinephrine if needed. 
During the first CPR cycle after randomization, patients in 
the VSE group received 40 mg of methylprednisolone and 
patients in the control group received saline placebo. Shock 
after resuscitation was treated with stress-dose hydrocortisone 
(VSE group) or saline placebo (control group; see below).
Patients in the VSE group vs. patients in the control 
group had higher probability for ROSC for 20 minutes or 
longer (83.9% vs 65.9%; OR 2.98; 95% CI 1.39 to 6.40) and 
survival to hospital discharge with good neurological outcome 
(13.9% vs 5.1%; OR 3.28; 95% CI 1.17 to 9.20). Results on 
the postresuscitation shock subgroup were also favorable for 
the VSE combination (see below). Table 1 displays important 
peri-arrest characteristics and variables of the pooled study 
population;65,67 these data are presented mainly to enable read-
ers to independently assess the baseline status of the 2 pooled 
groups. Figure 3 displays the pooled outcome data from the 
total of the 368 studied patients.
Both VSE studies exhibit limitations: results refer only to 
in-hospital cardiac arrest, there was no assessment of CPR 
quality, the VSE protocol did not allow a precise determina-
tion of the relative contribution of vasopressin and steroids to 
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the positive VSE group outcomes, there were some baseline 
imbalances with respect to cardiac arrest etiology and pre-
senting rhythm potentially favoring the VSE group (Table 1, 
footnote),68,69 and there was no pre-specified determination 
of 1-year outcomes. Also, in the second VSE study,67 attend-
ing physicians frequently prescribed open label, stress-dose 
hydrocortisone, especially to patients with high vasopressor 
requirements in the postresuscitation period; this caused 
cancellation of any further hydrocortisone or saline placebo 
administration according to patient randomization.67 Thus, 
although these results are considerably encouraging, they may 
require confirmation by a larger, international trial before 
potential incorporation into the CPR guidelines.70 Additional 
TABLE 1. Important baseline and peri-arrest characteristics of the pooled study populations of references 65 and 67.







Age - years 64.6 ± 18.5 63.8 ± 17.6
Male gender - no. (%) 117 (61.6) 125 (70.2)
Hypertension - no. (%) 110 (57.9) 95 (53.4)
Coronary disease - no. (%) 62 (32.6) 65 (36.5)
Diabetes - no. (%) 45 (23.7) 48 (27.0)
Hypotensionb 70 (36.8) 84 (47.2)
Respiratoryc 71 (37.4) 52 (29.2)
Myocardial ischemiac 36 (19.0) 42 (23.6) 
Metabolic 27 (14.2) 13 (7.3) 
Lethal Arrhythmia 14 (7.4) 10 (5.6) 
Other 2 (1.1) 6 (3.4)
VF/pulseless VT – no. (%) 30 (15.8) 29 (16.3) >0.99
Asystole – no. (%) 128 (67.4) 113 (63.5) 0.45
PEA – no. (%)c 32 (16.8) 36 (20.2) 0.42
Witnessed arrest - no. (%) 169 (89.0) 159 (89.3) >0.99
Location of cardiac arrest 
Hospital ward - no. (%)
Intensive care area - no. (%)
Emergency department - no. (%)










ALS duration, median (IQR) - min 20 (10-30) 14 (7-24) 0.01
Time to ALS initiation from emergency call - median (IQR; range) - min 1 (1-2; 0-4)d 1 (1-2; 0-4)e 0.16
Epinephrine dose, median (IQR) - mg 5 (3-9) 4 (2-6) 0.01
Rate of ROSC ≥20 min, after second vasopressor dose - no. (%) 33 (17.4) 50 (28.1) 0.02
Overall rate of ROSC – no (%) 118 (62.1) 148 (83.1) <0.001
VSE = vasopressin-steroids-epinephrine; VF = ventricular fibrillation; VT = ventricular tachycardia; PEA = pulseless electrical activity; ALS = 
advanced life support; IQR = interquartile range; ROSC = return of spontaneous circulation.
a, Baseline characteristics were not compared between the 2 groups. b, Imbalance potentially favoring control group outcomes68.
c, Imbalance potentially favoring VSE group outcomes68. d, Data available from 171 patients.
e, Data available from 159 patients.
CPR drug regimens supported by animal data and potentially 
warranting further clinical evaluation may include combined 
epinephrine, vasopressin, and nitroglycerin,71 epinephrine and 
atenolol,72 epinephrine and nitroglycerin,73 and epinephrine 
and levosimendan.74 
T h E  P O S T R E S U S C I T A T I O N  P h A S E
The high mortality rate of patients who initially achieve 
ROSC after cardiac arrest can be attributed to a pathophysi-
ological process that involves multiple organs. Although pro-
longed, whole-body ischemia initially causes global tissue and 
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in-hospital phase, and no generally accepted, evidence-based 
protocol exists, other than brain protection-oriented intensive 
care.
The AHA 2010 guidelines suggest a multiple system ap-
proach:78
Although 100% oxygen may have been used during initial 
resuscitation, providers should titrate inspired oxygen fraction 
(FiO2) as soon as possible to the lowest level required, ensur-
ing an adequate arterial oxygen content and avoiding oxygen 
toxicity. The optimal FiO2 is under debate. Animal data suggest 
that ventilation with 100% oxygen (generating a PaO2 of more 
than 350 mm Hg at 15 to 60 minutes after ROSC) increases 
brain lipid peroxidation, neuronal metabolic dysfunction and 
degeneration, and worsens short-term functional outcome 
when compared with ventilation with room air or an FiO2 
titrated to a pulse oximeter reading of 94% to 96%.79-84 Physi-
cians should try to achieve an arterial oxygen saturation of 
at least 94%, for all patients after ROSC. Hyperventilation 
should be avoided for its adverse hemodynamic effects, as 
well as for the potential vasoconstriction that low PaCO2 can 
cause in the cerebral circulation. Minute ventilation should 
be titrated targeting an end-tidal CO2 of 35 to 40 mmHg or a 
PaCO2 of 40 to 45 mmHg. Although human studies have not 
established ideal targets for blood pressure or blood oxygena-
tion,85,86 a mean arterial pressure of at least 65 mmHg and a 
central-venous oxygen saturation of at least 70% are generally 
considered as reasonable goals. Vasoactive drug infusions may 
be considered in order to achieve this goal.
Hyperglycemia87-91 or hypoglycemia92,93 can have detrimen-
tal effects on survival and neurological recovery. The optimum 
blood glucose concentration and interventional strategy to 
manage blood glucose in the post–cardiac arrest period is un-
known. Moderate glycemic control (144 to 180 mg/dL) seems 
reasonable in adult patients with ROSC after cardiac arrest. 
T h E R A P E U T I C  h y P O T h E R m I A
For protection of the brain and other organs, hypother-
mia is a helpful therapeutic approach in patients who remain 
comatose (usually defined as a lack of meaningful response 
to verbal commands) after ROSC.78 Questions remain about 
specific indications and populations, timing and duration of 
therapy, and methods for induction, maintenance, and subse-
quent reversal of hypothermia.
The recommended temperature of 32°C to 34°C has been 
extrapolated from experiments in animals;94,95 however, similar 
results have been observed with milder cooling.96 Although a 
Cochrane review supported these guidelines,97 some investiga-
tors have suggested a need for additional trials to confirm or 
refute this treatment strategy.98-100 
The use of therapeutic hypothermia is supported by the 
results of 2 prior, randomized, controlled trials of OHCA 
fIGURE 3. Cox regression analysis results on survival to hospi-
tal discharge with favorable neurological recovery {i.e. cerebral 
performance category (CPC) score of 1 or 2} in the pooled 
study population of references 65 and 67; Vasopressin-steroids-
epinephrine (VSE) group: 26/178 (14.6%); Control group: 9/190 
(4.7%). Randomization to the VSE group was associated with 
a lower probability for poor outcome [i.e. death during follow-
up, or survival to hospital discharge with a CPC score of 3 (se-
vere cerebral disability) or 4 (vegetative state)]: Hazard ratio 
0.67; 95% confidence interval 0.53 to 0.84; P<0.001. This origi-
nal, pooled analysis has been adjusted for initial cardiac arrest 
rhythm (i.e., shockable vs. non-shockable), resuscitation-asso-
ciated bicarbonate dose, time of cardiac arrest occurrence (i.e. 
night vs. morning-to-late evening hours or holiday vs. working 
day), and resuscitation-associated dose of epinephrine.
organ injury, while additional damage occurs during and after 
reperfusion.72,76 The unique features of post–cardiac arrest 
pathophysiology are often superimposed on the disease or 
injury that caused the cardiac arrest, as well as the underlying 
comorbidities. Therapies that focus on individual organs may 
compromise other injured organ systems. The four key com-
ponents of post-cardiac arrest syndrome are 1) post–cardiac 
arrest brain injury, 2) post–cardiac arrest myocardial dysfunc-
tion, 3) ischemia/reperfusion-triggered, systemic inflammatory 
response, and 4) persistent underlying pathology.77
The recognition of the importance of post resuscitation 
care on long term survival and favorable neurological outcome 
led to the addition of a fifth ring to the chain of survival, termed 
“post-resuscitation care”.
2 0 1 0  A h A  G U I D E L I N E S  f O R  P O S T -
R E S U S C I T A T I O N  C A R E – O V E R V I E W 
There is paucity of data reported from the post-arrest, 
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with a shockable rhythm that showed improved neurological 
outcomes in hypothermia-treated patients.101,102 In both trials, 
there were no pre-specified temperature control measures for 
control patients. Mild hypothermia (32-34°C) for 12 to 24 
hours improved neurological recovery and survival, despite 
delays of 4 to 8 hours in achieving goal temperatures.101,102 
Neutral results on hypothermia were reported by the 
investigators of a recent, international, multicenter, rand-
omized, controlled trial.103 This trial compared a target body 
temperature of 33°C with one of 36°C in patients resuscitated 
from OHCA of presumed cardiac cause.103 Hypothermia was 
induced as rapidly as possible with the use of ice-cold fluids, ice 
packs, and intravascular or surface temperature-management 
devices at the discretion of the attending physician. The time 
interval between ROSC and induction of hypothermia was 
20 to 240 min. There were no significant differences between 
the two groups in overall mortality at the end of the trial or in 
the composite outcome of poor neurologic function or death 
at 180 days.103
A difference between the recent trial103 and the earlier 
trials,101,102 is that the natural trajectory of temperature evolu-
tion was not allowed in either group. Indeed, temperature 
was actively controlled during the intervention period in both 
groups and fever was prevented during the first 3 days after 
cardiac arrest.103 As in the earlier trials,101,102 the investigators 
did enroll patients with OHCA of presumed cardiac cause, but 
the sample was larger and approximately 20% of participants 
had nonshockable rhythms.103 
Other published studies involving patients with cardiac 
arrest who were admitted to the ICU104-108 have shown base-
line characteristics and mortality that are in keeping with the 
findings of the recent, large trial.103 The mortality in both 
groups of this trial was lower than that in the control group 
of the Hypothermia after Cardiac Arrest trial.102 This can be 
attributed to the fact that both prehospital and critical care 
have improved during the past decade.106,109 Fever frequently 
develops after ROSC because of a systemic inflammatory 
response. Nevertheless, it is important to acknowledge that 
there may be a clinically relevant benefit of controlling the 
body temperature at 36°C, instead of allowing fever to develop 
in patients who have been resuscitated after cardiac arrest.110 
Bernard et al. conducted an investigation in 2010 inducing 
hypothermia in the field or after hospital admission in patients 
resuscitated from out of hospital arrest presenting with a 
shockable rhythm. No benefit was observed.111 The recent, 
large randomized trial by Kim et al found that prehospital, 
rapid infusion of up to 2 L of cold (4°C) normal saline did 
induce mild hypothermia, approximately 60 min faster than 
standard care, but did not improve survival or neurological 
status at discharge after resuscitation from prehospital, shock-
able (VF) or nonshockable (non VF) cardiac arrest.112 The 
intervention was associated with a significantly increased 
incidence of early re-arrest, and pulmonary edema/diuretic 
use (in the Emergency Department).
C O R T I C O S T E R O I D S
Corticosteroids are a class of chemicals involved in a wide 
range of physiological processes, including stress response, im-
mune response and regulation of inflammation, carbohydrate 
metabolism, protein catabolism, blood electrolyte levels, and 
behavior.
Preceding retrospective studies with inherent meth-
odological limitations did not support the use of low-dose 
corticosteroids during and after CPR.113,114 However, more 
recent laboratory data and clinical results are consistent with a 
possible, low-dose corticosteroid-associated, benefit in cardiac 
arrest, especially in patients with postresuscitation shock. Such 
potential benefit can be explained mainly by the hemodynamic 
and anti-inflammatory properties of hydrocortisone.115 
Cardioprotective effects of glucocorticoids in the acute 
setting of myocardial ischemia/reperfusion have been shown 
experimentally with regard to structural and functional myo-
cardial damage.116-123 Also, a meta-analysis of human data from 
11 controlled trials suggested a possible mortality benefit for 
corticosteroid treatment of myocardial infarction.124 
Glucocorticoids attenuate leukocyte/endothelium inter-
actions,125-128 as well as the generation and release of inflam-
matory cytokines and mediators.129-132 The Surviving Sepsis 
Campaign guidelines 2012 for the management of severe sepsis 
and septic shock suggest stress-dose hydrocortisone therapy 
(daily dose: 200 mg) only for patients who are poorly respon-
sive to fluid and vasopressor therapy.133 Likewise, in cardiac 
arrest patients, treatment-refractory shock is a common post-
ROSC complication.65,67 Furthermore, postresuscitation shock 
is frequently partly due to a post-arrest adrenal insufficiency 
or dysfunction,66,134-136 which in turn constitutes an independ-
ent predictor of mortality at one week after resuscitation.136
The mechanisms underlying the post-cardiac arrest syn-
drome involve a whole body ischemia and reperfusion that trig-
gers a systemic inflammatory response.65,66,77,78,134 Altogether, 
the high levels of circulating cytokines, the presence of endo-
toxin in plasma, and the dysregulated production of cytokines 
found in cardiac arrest patients resemble the immunological 
profile found in patients with sepsis.66,77,78, 134 
A recent, observational OHCA study found a 38% inci-
dence of bacteremia upon presentation to the Emergency 
Department.137 A similar incidence of cardiac arrest-associated 
bacteremia has been previously reported by others as well.138 
Consequently, actual septic insults may frequently contribute 
to the development and the severity of the postresuscitation 
hemodynamic instability. This fact, in conjunction with the 
lower absolute serum cortisol levels previously documented 
in patients with poor CPR/postresuscitation outcomes,135,139 
the previously reported, strong, negative correlation between 
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cortisol levels and “no-flow” time,139 and the frequently severe 
postresuscitation, hemodynamic instability that does not ad-
equately respond to fluid and vasopressor therapy,65,67 provides 
a robust framework for the rationale of glucocorticoid supple-
mentation in the peri-arrest and postresuscitation period.65,67,133 
In our recent in-hospital cardiac arrest studies,65,67 we 
administered 40 mg of methylprednisolone during CPR (in 
combination with vasopressin / epinephrine – see also above), 
and stress dose hydrocortisone (300 mg/day for a maximum 
of 7 days followed by gradual taper) to patients fulfilling a 
clearly defined criterion for postresuscitation shock. Patients 
with evidence of myocardial infarction received a 3-day course 
of stress dose hydrocortisone (followed by gradual taper), in 
order to prevent any potential retardation of infarct healing.65,67 
Compared to control, the postresuscitation shock subgroups 
of the VSE groups had improved post-arrest hemodynamics 
and central venous oxygen saturation,65,67 post-arrest cytokine 
levels65 and organ/system function,65,67 and survival to hospital 
discharge with favorable neurological recovery.65,67 According-
ly, pooled subgroup results show more VSE patients (23/103, 
22.3%) than control patients (6/88, 6.8%) with good functional 
outcome (hazard ratio for death during follow-up or severe 
cerebral disability / vegetative state: 0.64; 95% confidence 
interval 0.46 to 0.88; P=0.006).65,67
As already mentioned above, due to the VSE combination, 
we could not separately assess glucocorticoid efficacy.65,67,78 
Therefore, a large, multicenter, randomized, placebo-con-
trolled evaluation of stress-dose glucocorticoid supplementa-
tion in cardiac arrest is still needed.65,115 Such a study should 
provide definitive results on the efficacy, and appropriate 
dosage and timing of steroid administration. Lastly, although 
there is no published data suggestive of a glucocorticoid-
associated neuroprotection,65,67,77,78,115 recent laboratory results 
suggest that the biosynthetically related estrogens may actually 
mitigate the effects of global cerebral ischemia.140
B E T A  A D R E N E R E G I C  A N T A G O N I S T S
Two small, clinical, prospective human studies tested the 
effects of beta blockade against regular therapy in patients 
presenting with electrical storm. In the intervention group of 
the first study,141 sympathetic blockade resulted in a decline 
in the mean number of VF episodes from over 20 to 2.6 ± 1.7 
per day (P < 0.01). In contrast, 91% of patients in the control 
group continued to have VF episodes. At the end of the first 
year of follow-up, 18/27 patients in the beta blockade group 
were still alive, compared with 1/22 in the control group. In 
the other human trial,142 42 consecutive patients with electri-
cal storm refractory to regular ALS therapy received intrave-
nous landiolol in increasing doses (starting at 2.5 μg/kg/min; 
maximum dose was 80 μg/kg/min), subsequently titrated to the 
minimum infusion rate required for arrhythmia control. The 
study protocol was ineffective in 9 patients (21%), who died 
of arrhythmia. From the 33 responders, 21 received carvedilol 
and 12 were started on bisoprolol, with oral beta-blocker ad-
ministration immediately after stabilization. Eight of these 33 
patients (19%) died afterwards from multiple organ failure or 
infection, and 25 (60%) survived to hospital discharge.
A recently published review on the use of beta-blockers 
in cardiac arrest with shockable rhythms concluded that 
available human studies may point toward a beneficial effect 
of beta-blockade in patients, which is in accordance with the 
results from the majority of relevant clinical case reports and 
animal experimental studies.143 However, high quality human 
trials are warranted, in order to reliably evaluate the poten-
tial usefulness of the beta-blockers in cardiac arrest. Indeed, 
beta-blockers may counteract the potentially deleterious beta-
adrenergic effects of epinephrine, which may contribute to the 
postresuscitation myocardial dysfunction and the recurrence 
of life-threatening arrhythmias.
O T h E R  A N T I A R R h y T h m I C  D R U G S
Amiodarone affects sodium, potassium, and calcium chan-
nels and has alpha and beta adrenergic blocking properties.40 
It can be given as an initial IV bolus of 300 mg to patients 
with refractory VF/VT cardiac arrest not responsive to CPR, 
defibrillation (i.e. 3 shocks), and vasopressors. If VF/VT per-
sists after the 4th shock, an additional amiodarone IV bolus of 
150 mg may be considered.40 Amiodarone effectiveness with 
respect to improved survival to hospital admission of OHCA 
patients is supported by the results of 2 blinded, randomized, 
controlled trials.144,145 If amiodarone is not available, the so-
dium channel blocker lidocaine may be given with an initial 
IV bolus of 1-1.5 mg/kg, followed by additional IV boluses of 
0.5-0.75 mg/kg every 5-10 min and up to a total dose of 3 mg/
kg.40 Lastly, IV magnesium sulfate can be given exclusively for 
the treatment of irregular/polymorphic VT associated with 
prolonged QT interval.40,146,147
N I T R A T E S
The greatest proportion of in-hospital, post-resuscitation 
mortality is caused by global ischemic brain injury, whereas 
both myocardial dysfunction and systemic inflammation 
predispose to poor neurological outcome.148 Mechanisms of 
post-resuscitation brain injury include excitotoxicity, free radi-
cal formation, pathological activation of proteases, and cell 
death signalling.77,149 The injurious pathways include disruption 
of the blood–brain barrier, neuro-inflammation, and delayed 
neuro-degeneration.148,150 
Nitrite therapy limits cellular injury and apoptosis after 
ischemia and reperfusion (I/R).151 It has been proven to be 
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cytoprotective in numerous animal models of focal I/R in-
jury, including rodent heart, brain, liver and kidney, canine 
heart, and primate brain.151-155 Systemic nitrite reduction by 
ceruloplasmin knockout or dietary nitrate/nitrite elimination 
increased infarction volume in the liver and heart after experi-
mental ischemia.156,157 These studies indicate that physiological 
systemic nitrite levels modulate host resilience to ischemia. 
The established safety of human and animal nitrite dosing158 
and its potent effects in limiting major organ injury suggest 
that nitrite represents an ideal candidate for the treatment of 
cardiac arrest.
Nitric oxide (NO) is produced from NO synthases (NOS, 
i.e. NOS1, NOS2, and NOS3). NO exerts a number of effects 
that would be expected to be beneficial during I/R injury.159 NO 
is a potent vasodilator which inhibits platelet and leukocyte ac-
tivation and adhesion, inhibits reactive oxygen species (ROS)-
producing enzymes, and directly scavenges ROS.160 Studies 
using NOS3 knockout mice showed that NOS3 deficiency 
aggravates I/R injury in the brain and heart,161,162 whereas 
cardiomyocyte-specific overexpression of NOS3 attenuated 
postresuscitation myocardial and neurological dysfunction in 
NOS3-deficient mice.163
Several recent studies are also consistent with a nitrite 
treatment/NO associated benefit in experimental cardiac 
arrest.71,73,164-169 Likely mechanisms of brain protection may 
involve the primary intra-cellular target of NO, i.e. soluble 
guanylate cyclase,167 or increased levels of neuronal nitrite and 
S-nitrosothiols.168 The neuroprotective effects of hypothermia 
seem to be at least partly mediated through enhanced NOS3 
signalling.169 Also, inhaled NO (40 ppm) improves neurological 
outcomes during concurrent use of hypothermia.169
In contrast to NO, NO-donor compounds may induce 
systemic vasodilation and hypotension, frequently precluding 
their use in the setting of cardiac arrest-associated hemody-
namic instability. On the other hand, inhaled NO is a selec-
tive pulmonary vasodilator that does not produce systemic 
hypotension when inhaled at concentrations of up to 80 ppm 
in multiple species, including man.170 The absence of systemic 
vasodilation during NO inhalation is due to the rapid scaveng-
ing of NO by hemoglobin in the blood.
Some NO, once inhaled, may escape scavenging by hemo-
globin and be converted to relatively stable NO metabolites 
(e.g., nitrite and S-nitrosothiols) that can regenerate NO in the 
periphery.171 NO inhalation has been associated with marked 
increases in the arterial blood concentration of NO metabo-
lites.172 Also, regenerated NO may exert regional vasodilating 
effects. Indeed, a recent study by Terpolilli et al,173 showed 
that NO inhalation prevented ischemic brain injury in mice 
and sheep by selective dilatation of collateral arterioles. The 
aforementioned, promising, experimental results provide a 
robust background for a possible, future evaluation of nitrates/
NO in the clinical setting.
C O N C L U S I O N S
Our clinical knowledge and practices with respect to the 
management of cardiac arrest have substantially improved 
during the last 10-15 years. This has resulted in significant 
improvements in the survival with favorable neurological out-
come. Furthermore, recent, promising study results may guide 
future research aimed at establishing definitive evidence for 
more effective therapeutic approaches during CPR and ALS, 
as well as during the postresuscitation period.
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